JS Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

JS Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000,000	Closed	-$16.4M	–	38
2021 Q4	$16.4M	Hold	1,000,000	–	–	0.74%	24
2021 Q3	$9.95M	Hold	1,000,000	–	–	0.58%	28
2021 Q2	$9.98M	Hold	1,000,000	–	–	0.48%	31
2021 Q1	$9.96M	Buy	+1,000,000	New	+$10.3M	0.52%	33

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FCOMV

Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

JS Capital Management's PRDS Position: Q1 2022 in Review

JS Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q1 2022, closing a stake of 1,000,000 shares — an estimated $16.4M sold.

JS Capital Management first reported a position in PRDS in Q1 2021 and held it in 4 quarters. The position peaked at $16.4M in Q4 2021. 57 funds tracked by Wall St. Rank hold PRDS as of Q1 2022.

JS Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
JS Capital Management sold 1,000,000 Pardes Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $16.4M.
JS Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
JS Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $16.4M in Q4 2021.
57 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q1 2022.

Based on JS Capital Management's 13F filing for Q1 2022, filed 16 May 2022.